CD8A and neoplasm: In the same context, Huang et al., explored the tumor suppressor and immune-activating effects of an in-situ DC vaccine (HELA-Exos) in immunocompetent mice and TNBC patient-derived organoids and showed that HELA-Exos possessed a profound ability to augment type one conventional dendritic cell (cDC1) antigen cross-presentation and tumor-reactive CD8+ T-cell generation, hence leading to potent TNBC inhibition [38].